GLPwatch
Papers (9189)
Page 101 of 154, ranked by citation count.
- The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.
- Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus.
- The effect of exenatide and erythromycin on postprandial symptoms and their relation to gastric functions.
- A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
- Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway.
- Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
- 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide.
- Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.
- Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
- Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
- Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).
- Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
- Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
- Liraglutide for Adolescents with Obesity.
- Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
- Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes.
- GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024.
- The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.
- Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
- Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study.
- The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression.
- Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.
- Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.
- Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study.
- Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial.
- Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
- Greater Combined Reductions of HbA<sub>1c</sub> ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
- Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
- iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
- Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.
- Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.
- Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
- GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
- Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
- Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.
- New insight on the role of liraglutide in alleviating dexamethasone-induced pancreatic cytotoxicity via improving redox status, autophagy flux, and PI3K/Akt/Nrf2 signaling.
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
- Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.
- Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
- Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.
- [Effects of Exenatide-4 on proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells].
- Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.
- Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.
- Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
- Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
- Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
- Tackling Cravings in Medical Weight Management: An Update on Pathophysiology and an Integrated Approach to Treatment.
- Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
- Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
- Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis.
- Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.
- Optimizing weight control in diabetes: antidiabetic drug selection.
- [Liraglutide attenuates myocardial ischemia/reperfusion injury possibly through reducing cardiomyocytes apoptosis and oxidation in rats].
- Electrochemical Sensing of the Peptide Drug Exendin-4 Using a Versatile Nucleic Acid Nanostructure.
- [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver].